Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Canesten HC cream	TA85 - Frequency of application of topical corticosteroids for atopic eczema	Mild steroid potency.
Cannabidiol (Epidyolex®)	TA614 - Cannabidiol with clobazam for treating seizures associated with Dravet Syndrome TA615 - Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome
Capecitabine tablets	TA61 - Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer TA100 - Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer TA191 - Capecitabine for the treatment of advanced gastric cancer TA263 - Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer TA62 - Guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer
Caplacizumab (Cablivi®)	TA667 - Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura
Carboplatin injection	TA55 - Guidance on the use of paclitaxel in the treatment of ovarian cancer TA91 - Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer
Carfilzomib	TA457 - Carfilzomib for previously treated multiple myeloma	For hospital use only
Carfilzomib (Kyprolis®)	TA657 - Carfilzomib for previously treated multiple myeloma TA695 - Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma
Carmustine 7.7mg implants	TA121 - Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma TA149 - Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal)	For hospital use only
Casirivimab plus imdevimab (Ronapreve®)	TA878 - Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
Cemiplimab	TA802: Cemiplimab for treating advanced cutaneous squamous cell carcinoma

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.